Novo's Oral Diabetes Drug Hits Heart-Safety Goal in Study

(Bloomberg) -- Novo Nordisk A/S’s tablet version of its Ozempic injection for diabetes hit a heart-safety goal in a study that compared it with standard treatment alone.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.